Table 4

Mean proportion of patients controlled for 95% of study period

Study[Ref.]TreatmentPercentage of patients controlled for 95% of days during weeks 5–12 (95% CI) Measure of control
Level 1Level 2Level 3
A1 9 a SFC13 (6–20)27 (18–36)45 (35–55)
SALM3 (-1–7)5 (1–10)17 (9–25)
FP2 (-1–5)10 (4–16)26 (17–35)
PLa1 (-1–3)3 (-1–7)15 (7–23)
A2 10 b SFC9 (3–15)27 (17–37)49 (38–60)
SALM0 (0–0)4 (0–8)24 (15–33)
FP4 (0–8)16 (8–24)39 (28–50)
PL1 (-1–3)3 (-1–7)28 (19–37)
B1 11 SFC7 (2–12)13 (7–19)30 (22–38)
SALM + FP concurrently10 (5–15)18 (11–25)31 (23–39)
B2 12 SFC5 (2–8)10 (6–15)22 (16–28)
SALM + FP concurrently3 (1–6)7 (3–11)21 (15–27)
B3 13 SFC8 (4–12)13 (8–18)24 (17–31)
SALM + FP concurrently7 (3–11)11 (6–16)21 (15–27)
FP4 (1–7)4 (1–7)18 (12–24)
B4 14 SFC7 (2–12)15 (9–21)29 (21–37)
SALM + FP concurrently5 (1–9)10 (5–15)29 (21–37)
C1 15 SFC20 (14–26)27 (20–34)36 (29–43)
BUD15 (10–20)20 (14–26)34 (27–41)
C2 16 SFC11 (6–16)17 (11–23)23 (17–29)
BUD5 (2–8)7 (3–11)12 (7–17)
  • 95% CI: 95% confidence interval; a: approximately 70% of patients were previously taking inhaled corticosteroids; b: all patients were previously taking inhaled corticosteroids; BUD: budesonide; FP: fluticasone propionate; PL: placebo; SALM: salmeterol; SFC: salmeterol/fluticasone propionate combination product.